Regentis Biomaterials (NYSE American: RGNT) is strengthening the manufacturing and intellectual property foundation behind its GelrinC cartilage-repair technology as it moves toward broader commercialization. The company recently received a Japanese Notice of Allowance for patent protection covering the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC. This followed a recent U.S. issuance that expanded its global IP portfolio to nearly 30 patents. Regentis’ proprietary manufacturing process increases yield fivefold, simplifies production and is built to support commercial-scale manufacturing—important advantages for an off-the-shelf cartilage-repair product designed to avoid the complexity and cost of cell-based procedures. The milestone comes as the company begins European commercialization efforts following CE Mark approval and advances its pivotal U.S. trial beyond 50% enrollment, with premarket approval preparation targeted for the end of 2027.
To view the full article, visit https://ibn.fm/ILwoP
About Regentis Biomaterials Ltd.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
